Alira Health

Alira Health
Filtering options
Pharma
MedTech
EU
US
M&A
CDD/VDD
Asia-Pac
Biotech
CDMO
Medical Devices
Digital Therapeutics
Pharma

Strategic and Financial Advisor: Klinge Biopharma GmbH enters into an exclusive licensing and supply agreement with MS Pharma

Alira Health has acted as the exclusive financial and strategic advisors to Klinge Biopharma GmbH, licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea® (Aflibercept), in the Middle East and North Africa.
CDD/VDD Digital Therapeutics

CDD Advisor: TVM Capital Healthcare Invests in neurocare Group AG

Alira Health advised TVM Capital Healthcare on an investment into neurocare group AG. The Munich-based leader in personalized mental health care is set to receive a US$ 17 million boost from TVM Capital Healthcare, a specialist healthcare private equity firm.
MedTech CDD/VDD CDMO

CDD Advisor: Trill Impact Enters a Strategic Alliance with TT medic

Alira Health advised Trill Impact, a pioneering Impact House with around EUR 1.2 billion in assets under management, joining forces with TT medic GmbH, a medtech development and manufacturing partner for high-quality polymer components operating in Austria, Switzerland and Germany.
Pharma CDD/VDD

Advisor: CNX Therapeutics in the Commercial and Strategic Due Diligence of Two CNS Products Acquired from Eisai

Alira Health advised CNX Therapeutics, a UK-based specialty pharmaceutical company, in the Commercial and Strategic Due Diligence of two CNS products acquired from Eisai, Loxapac® and Parkinane LP®. Addressing psychological disorders and Parkinson’s disease respectively, the acquisition of these two medicines will enable CNX Therapeutics to set up its presence in France while further strengthening its CNS portfolio.
Pharma EU M&A

Aesculapius Farmaceutici Srl sells to Ceres Pharma NV

Alira Health advised Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC drugs, food supplements and raw materials, in the sale to Ceres Pharma. The transaction is expected to further expand Ceres Pharma’s presence in Italy and the business combination will create value for the pharmaceutical ecosystem via enhanced distributions and commercialization capabilities of the combined entity. We were honored to serve as a transaction advisor representing the seller in this landmark deal.
2024
Pharma CDD/VDD

CDD Advisor: Alcami acquires Pacific Pharmaceutical Services

Alira Health advised Alcami, a leading Contract Development Manufacturing Organization headquartered in North Carolina, with CDD support in its acquisition of PPS, a West Coast-based biostorage company. This investment will enable bicoastal geographic expansion of Alcami’s Pharma Storage and Services capabilities, thus allowing it to serve all US biotech and pharma hubs.
AliraHealth TVM DEBx
2023
CDD/VDD Medical Devices

CDD Advisor: TVM Capital Healthcare invests in DEBx Medical

Alira Health advised TVM Capital Healthcare, a global specialist healthcare private equity firm headquartered in Dubai and Singapore, with CDD support in its multi-million euro investment in DEBx Medical, an Amsterdam-based medical devices company. The investment will accelerate the introduction of the DEBx Medical solution, DEBRICHEM®, an innovative product for treating non-healing chronic wounds that is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds.
2023
MedTech US CDMO

Natech Plastic sells to Stratec SE

Alira Health advised Natech Plastic, a leading contract development and manufacturing company specialized in precision life sciences consumables, in the sale to Stratec SE. The transaction is expected to boost Stratec’s presence in the North American market and the business combination will create value for the in-vitro diagnostics ecosystem via enhanced innovation and manufacturing capabilities. We were honored to serve as the sellers’ advisors in this important deal.
Load more
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.